25 Sep 2025 – Bramble Bio today announced a strategic manufacturing partnership with Keli Therapeutics to advance KELI-101, a novel cell therapy targeting acute kidney injury (AKI) following cardiac bypass surgery (CPB-AKI). This serious inflammatory complication often progresses to chronic kidney disease, leaving patients with limited treatment options. By pairing Keli’s breakthrough therapy with Bramble Bio’s advanced cGMP manufacturing expertise, the companies aim to deliver the first effective intervention that can prevent long-term kidney damage and improve patient outcomes.

Addressing a Critical Unmet Need
AKI after cardiac bypass surgery is a frequent and severe condition that significantly increases the risk of chronic kidney disease, long-term dialysis, and healthcare costs. Keli’s lead therapy, KELI-101, is designed to intervene early, preventing the cascade of inflammation and organ damage that drives disease progression. Justinas Maciulaitis, CEO of Keli Therapeutics, commented:

“During our preclinical studies, we demonstrated that KELI-101 improves survival rate, possesses anti-inflammatory and immunomodulatory properties to mitigate kidney damage, and can halt the progression to chronic kidney disease. These results represent a major advancement in post-surgical AKI treatment and offer a promising new approach to patient care.
KELI-101 is positioned to redefine the standard of care in CPB-AKI by improving patient outcomes and reducing the long-term healthcare costs of chronic kidney disease. Most importantly, its multifactorial mode of action opens the door to future use in a wide range of acute and chronic inflammatory conditions worldwide.”

A Novel Cell Therapy Platform
Keli Therapeutics has developed activated perinatal-origin mesenchymal stromal cells (MSCs) that are up to 20 times more potent than standard MSCs. These next-generation cells are primed for stronger immunomodulation and efficacy, addressing a key limitation of conventional MSC therapies. With Bramble Bio’s breadth of experience and operational scalability, this innovation has the potential to deliver global therapeutic impact.

Broader Potential
Beyond AKI, Keli’s activated perinatal MSC platform holds promise across a wide range of inflammatory and degenerative conditions, including graft-versus-host disease, inflammatory bowel disease, rheumatoid arthritis, and neuroinflammatory disorders—underscoring its potential as a platform technology for next-generation therapies.

Bramble Bio’s Commitment

“We are delighted to support Keli Therapeutics in advancing KELI-101 into the clinic” said Simon Boa, Managing Director of Bramble Bio.

“Acute kidney injury remains a major challenge with no effective treatments, and Keli’s approach could transform care for patients at risk of long-term kidney damage. At Bramble Bio, our mission is to enable breakthrough science through world-class manufacturing, and we are excited to help bring this important therapy closer to patients.”

________________________________________
About Bramble Bio
Bramble Bio is a leading Contract Development and Manufacturing Organization (CDMO) dedicated to advancing the cell and gene therapy industry. The company provides end-to-end support, including process development, optimization, and cGMP-compliant manufacturing for advanced therapy medicinal products (ATMPs). With deep expertise in cell and gene therapy platforms, Bramble Bio partners with innovators worldwide to translate groundbreaking science into scalable, high-quality therapies. Its mission is to enable the successful development and delivery of transformative treatments that improve patient lives globally.

About Keli Therapeutics
Keli Therapeutics is a clinical-stage biotechnology company advancing next-generation cell therapies for serious inflammatory and degenerative diseases. Its lead program, KELI-101, is in clinical development for acute kidney injury (AKI) following cardiac bypass surgery, a life-threatening condition with no effective therapies. Built on a proprietary platform, Keli Therapeutics is building a pipeline with potential applications across autoimmune disorders, inflammatory and fibrotic diseases, and degenerative disorders. Keli Therapeutics’ mission is to deliver innovative therapies that redefine standards of care and improve patient lives worldwide.